|Bid||47.02 x 900|
|Ask||47.05 x 800|
|Day's Range||47.03 - 47.56|
|52 Week Range||35.10 - 48.11|
|Beta (3Y Monthly)||0.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.56|
With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.
Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.
National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.
A study by TeleFlex (TFX) sheds light on the real-world retrospective data on 30 men suffering urinary retention treated with the UroLift System.
Hologic, Inc. (HOLX), an innovative medical technology company focused on improving women’s health and well-being through early detection and treatment, today opened its first Learning and Experience Centre in Zaventem, Belgium (a municipality neighboring Brussels). The state-of-the-art facility provides comprehensive training for customers, healthcare professionals and employees across Hologic’s Europe, Middle East and Africa (EMEA) region, centralizing the education experience for Hologic’s technologies.
Phibro Animal (PAHC) has been gaining from strong volume growth in foreign markets. However, adverse currency movements remain a concern.
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.
The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.
Align Technology (ALGN) will be integrating Digital Smile Design's methodology in functional and aesthetic dentistry with its end-to-end digital workflow covering iTero scanners and Invisalign system.
Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.
Hologic (HOLX) looks stronger than Varian Medical (VAR) when it comes to current-year earnings projections as well as fundamentals.
Hologic Inc NASDAQ/NGS:HOLXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for HOLX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $3.44 billion. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you canRead More...
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Hologic, Inc. (HOLX) announced today that it has received a CE mark in Europe for its Omni™ hysteroscope, an innovative three-in-one modular scope with advanced visualization capabilities designed for both diagnostic and therapeutic hysteroscopic procedures. Obstetricians and gynecologists (ObGyns) can use the new Omni hysteroscope in out- and in-patient settings. “Experts agree that direct visualization of the uterine cavity in women with abnormal uterine bleeding is the gold standard that allows ObGyns to accurately identify and collect quality samples and remove pathology – in a safer and more effective manner than blind biopsy and curettage,”1 said Edward Evantash, M.D., Medical Director and Vice President of Global Medical Affairs, Hologic.